Clinical Trials Browser

OTHER × Has results × Gemcitabine × Clear all

NCT03366766 2026-02-20

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

Phase 2 Terminated

14 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT02422381 2026-02-18

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Active not recruiting

16 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03123276 2026-02-13

GEMMK

Phase 1/2 Completed

25 enrolled 15 charts

Sarcoma

NCT02690558 2026-01-28

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Phase 2 Active not recruiting

39 enrolled 16 charts

Urinary Bladder Neoplasms

NCT04524702 2026-01-23

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Phase 2 Completed

10 enrolled 13 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04203160 2025-12-31

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

Phase 1/2 Terminated

75 enrolled 17 charts

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT02611037 2025-12-18

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

Phase 2 Completed

34 enrolled 12 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT03910387 2025-12-16

Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

Phase 2 Completed

23 enrolled 15 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04386746 2025-11-17

GEMDOCE

Phase 2 Active not recruiting

27 enrolled 9 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01270724 2025-10-27

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

Phase 2 Completed

10 enrolled 8 charts

CNS Germ Cell Tumor

NCT01972919 2025-10-27

MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

23 enrolled 8 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01495676 2025-10-10

GETUGV04

Phase NA Terminated

69 enrolled 9 charts

Urinary Bladder Neoplasms

NCT02621151 2025-10-07

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

Phase 2 Active not recruiting

60 enrolled 11 charts

Muscle-invasive Urothelial Cancer of the Bladder

NCT03579771 2025-08-15

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Phase 2 Completed

30 enrolled 13 charts

Gastrointestinal

Cholangiocarcinoma

NCT03697564 2025-08-06

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

Phase 2 Completed

2 enrolled 10 charts

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03739619 2025-08-06

Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1/2 Completed

3 enrolled 10 charts

Hodgkin Disease

NCT02769832 2025-07-29

Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

Phase 2 Completed

32 enrolled 12 charts

Small Cell Lung Carcinoma

NCT02723331 2025-07-01

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

Phase 2 Completed

48 enrolled 13 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03783949 2025-06-11

EUDARIO

Phase 2 Completed

122 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04581343 2025-05-04

PanCAN-SR1

Phase 1 Completed

10 enrolled 26 charts

Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT04602078 2025-04-24

AUREA

Phase 2 Completed

82 enrolled 20 charts

Carcinoma, Transitional Cell, Neoplasm Metastasis, Neoplasms

NCT02365766 2025-03-18

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

Phase 1/2 Completed

83 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02506959 2025-03-18

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Phase 2 Completed

83 enrolled 11 charts

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Plasmacytoma

NCT00446225 2025-03-05

EURTAC

Phase 3 Completed

174 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01701986 2025-02-28

Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Phase 1/2 Completed

64 enrolled 13 charts

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, T-Cell

NCT00544414 2025-02-19

Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer

Phase 2 Completed

31 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03535727 2024-12-31

A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer

Phase 1/2 Completed

48 enrolled 24 charts

Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms, Glandular and Epithelial, Pancreatic Diseases, Pancreatic Neoplasms

NCT01905150 2024-12-11

Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer

Phase 2 Completed

34 enrolled 10 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02312245 2024-12-05

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

13 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04989218 2024-11-05

ICC

Phase 1/2 Terminated

1 enrolled 11 charts

Gastrointestinal

Cholangiocarcinoma

NCT02692248 2024-10-10

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT

Phase 2 Completed

64 enrolled 17 charts

Lymphoma, Large B-Cell, Diffuse

NCT00936936 2024-08-26

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

Phase 2 Completed

64 enrolled 10 charts

Testicular Neoplasms

NCT02352337 2024-07-10

PANOPTIMOX

Phase 2 Completed

276 enrolled 12 charts

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03558087 2024-06-27

Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

Phase 2 Completed

76 enrolled 14 charts

Urinary Bladder Neoplasms

NCT03451331 2024-05-16

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Phase 2 Completed

49 enrolled 15 charts

Metastatic Urothelial Cancer

NCT04088188 2024-05-06

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Phase 1 Terminated

8 enrolled 14 charts

Gastrointestinal

Cholangiocarcinoma

NCT03848182 2024-04-18

Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer

Phase 2 Terminated

10 enrolled 7 charts

Gastrointestinal

Pancreatic Neoplasms, Lipodystrophy, Congenital Generalized

NCT02395016 2024-04-04

A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer

Phase 3 Completed

90 enrolled 18 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04430036 2024-04-04

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

Phase 2 Terminated

4 enrolled 9 charts

Urinary Bladder Neoplasms

NCT00863369 2024-03-20

Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Completed

33 enrolled 14 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03519308 2024-03-15

A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Phase EARLY_PHASE1 Terminated

3 enrolled 13 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00617656 2024-01-30

BREC

Phase 3 Terminated

382 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00679029 2023-12-11

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Phase 2 Terminated

15 enrolled 9 charts

Breast Neoplasms

NCT01897454 2023-12-05

Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer

Phase 2 Terminated

23 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02887248 2023-12-05

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Phase 2 Terminated

3 enrolled 9 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03649321 2023-11-09

Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer

Phase 1/2 Terminated

9 enrolled 12 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02178436 2023-11-07

Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Phase 1/2 Completed

15 enrolled 13 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02243358 2023-10-27

Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Phase 2 Completed

24 enrolled 5 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02383433 2023-10-23

Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer

Phase 2 Terminated

2 enrolled 8 charts

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT03714555 2023-10-18

Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

Phase 2 Terminated

1 enrolled 7 charts

Gastrointestinal

Pancreatic Neoplasms